Historical Information

Conference call begins today at 4:30 p.m. Eastern Time   BASKING RIDGE, N.J. (March 15, 2018)  – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular

BASKING RIDGE, N.J. (March 13, 2018)  – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that the first patient has

BASKING RIDGE, N.J. (March 9, 2018)  – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, today announces that management will be

Treatment continues to be well-tolerated and deemed non-futile for therapeutic effect BASKING RIDGE, N.J. (March 8, 2018) – Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune

License Expands Pipeline in Cardiovascular Disease based on Compelling Data Showing Improvement in Chest Pain, Exercise Capacity and Mortality BASKING RIDGE, N.J. (March 6, 2018)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical

BASKING RIDGE, N.J. (February 7, 2018)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, today announces that management will be

Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes Primary endpoint topline data to be reported in early 2019 BASKING RIDGE, N.J. (January 18, 2018)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a

BASKING RIDGE, N.J. (December 1, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces today that David J.

Conference call begins today at 4:30 p.m. Eastern Time   BASKING RIDGE, N.J., (November 9, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS)  (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology

BASKING RIDGE, N.J. (November 2, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release